As Patrick F. Fogarty, MD, briefly discusses the improvements in the length of time of which new factor 8 and factor 9 protein products extend treatment for hemophilia patients and stresses why it is important for clinicians to work together to ensure that their patients have access to these longer-acting agents, the panelists consider issues that should be addressed by managed care professionals and clinicians.
From an economic standpoint, Hugh Fatodu, RPh, MBA, explains that longer-acting agents lead to more product waste and states that a large amount of unused product sits inside the patient’s home. However, he believes that specialty pharmacies can help improve the amount of inventory that is provided to patients.
Maria Lopes, MD, MS, and Mr Fatodu explain that to improve the amount of protein product administered to the patient and to reduce the amount of product waste, it is key to determine how much of the drug is necessary to the patient and develop a fair balance plan.
Dr Lopes and Mr Fatodu explain that the end result of practicing fair balance should minimize waste by recommending lower dosage requirements, yet should ensure that patients do not have bleeding episodes.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen